Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Durvalumab in Combination With Standard Chemotherapy Doxorubicin for Advanced Soft Tissue Sarcoma

NCT03802071 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT03802071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03802071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Durvalumab in Combination With Standard Chemotherapy Doxorubicin for Advanced Soft Tissue Sarcoma
Lead sponsor
Yonsei University
Phase
Phase 1/2
Overall status
Completed
Start date
September 16, 2019
Completion date
August 10, 2022
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma